Entera Bio Ltd. Form 8-K Filing

On April 1, 2026, Entera Bio Ltd. entered into a Securities Purchase Agreement with funds affiliated with BVF Partners LP for a private placement of 7,827,789 units. Each unit consists of one ordinary share (or a pre-funded warrant in lieu thereof) and one warrant to purchase 1.5 ordinary shares. The aggregate proceeds were approximately $10.0 million, with a price of $1.2775 per unit. The closing occurred on April 2, 2026. Pre-funded warrants have an exercise price of NIS 0.0000769 and no expiration date, subject to a 4.99% beneficial ownership limit. Ordinary share warrants have an exercise price of $1.24, become exercisable six months after closing, and expire five years from issuance, also subject to a 4.99% ownership limit. If all ordinary share warrants are exercised for cash, the company expects to receive an additional $14.5 million. The net proceeds will be used to initiate Phase 3 trials for EB613 in osteoporosis and for general working capital. The securities were offered under Section 4(a)(2) of the Securities Act, relying on the purchaser being an accredited investor. A Registration Rights Agreement was also entered into, requiring the company to file a registration statement within 30 days of closing to register the resale of shares issuable upon exercise of warrants.